301257 SMO Clinplus
- 44.57
- -0.02-0.04%
SMO Clinplus News
Major shareholders of Prius (301257.SZ) believe Zhaotai will reduce its holdings by 1%
Prius (301257.SZ) announced that Shanghai Guanyu Investment and Development Co., Ltd., the shareholder of the company holds more than 5% of the shares - Guan...
Prius (301257.SZ): Services can cover 24 fields such as hematological tumors, thoracic tumors, digestive tumors, urinary tumors, and rare diseases
Glonghui, May 9 | Prius (301257.SZ) said on the investor interactive platform that as a big data-driven clinical trial service provider, the company provides full-process clinical trial management services for domestic and foreign pharmaceutical companies and other customers. The services can cover 24 fields including hematological tumors, thoracic tumors, digestive tumors, urinary tumors, and rare diseases.
Prius (301257.SZ): Currently, the current service does not cover biosynthesis related fields
On May 9, GLONGHUI (301257.SZ) said on the investor interactive platform that the company, as a big data-driven clinical trial service provider, provides professional clinical research services involving clinical trials phase I to phase III, post-marketing clinical trial stages and real-world research according to the drug research and development process. Currently, the company's existing services do not cover fields related to biosynthesis.
Prius (301257.SZ): As of December 2023, the company has promoted the listing of 61 new oncology drugs and 11 tumor biosimilar or chemical generic products at home and abroad
Glonghui, May 9 | Prius (301257.SZ) said on the investor interactive platform that by the end of March 2024, the company had undertaken more than 3,100 international and domestic clinical projects and participated in many popular domestic and foreign projects. The service can cover 24 fields such as hematological tumors, thoracic tumors, digestive tumors, urinary tumors, rare diseases, etc., and has a great competitive advantage in various disease segments such as hematological tumors, thoracic tumors, digestive tumors, cardiovascular diseases, and urological tumors. In the field of oncology, as of December 2023, the company has promoted 61 new oncology drugs and 11
SMO ClinPlusLTD's (SZSE:301257) Earnings Are Of Questionable Quality
Despite posting some strong earnings, the market for SMO ClinPlus CO.,LTD.'s (SZSE:301257) stock hasn't moved much. We did some digging, and we found some concerning factors in the details. SZSE:3
Prius (301257.SZ) announced its 2023 annual results, with net profit of 135 million yuan, an increase of 86.06% over the previous year
Prius (301257.SZ) released its 2023 annual report. The company achieved operating income of 7.6 during the reporting period...
Retail Investors Invested in SMO ClinPlus CO.,LTD. (SZSE:301257) Copped the Brunt of Last Week's CN¥379m Market Cap Decline
Key Insights The considerable ownership by retail investors in SMO ClinPlusLTD indicates that they collectively have a greater say in management and business strategy A total of 6 investors have a m
Prius (301257.SZ): Actual controller Lai Chunbao completed an increase of 160,000 shares
Gelonghui, Feb. 7 | Prius (301257.SZ) announced that as of the announcement disclosure date, the company's chairman and actual controller Mr. Lai Chunbao's plan to increase his holdings had been completed. On February 7, 2024, Mr. Lai Chunbao increased his holdings of the company's shares by 160,000 shares through centralized bidding through the Shenzhen Stock Exchange trading system, accounting for 0.26% of the company's total share capital. The increase in holdings was 6,544,987 yuan (not including transaction fees). The increase amount of the above holdings increase entity has exceeded the lower limit of the amount of the plan to increase their holdings.
The actual controller of Prius (301257.SZ) plans to spend 5 million yuan to 8 million yuan to increase its holdings
Prius (301257.SZ) issued an announcement. Lai Chunbao, the actual controller of the company, plans to increase his holdings from the date of the announcement of this plan...
Is Weakness In SMO ClinPlus CO.,LTD. (SZSE:301257) Stock A Sign That The Market Could Be Wrong Given Its Strong Financial Prospects?
SMO ClinPlusLTD (SZSE:301257) has had a rough three months with its share price down 39%. But if you pay close attention, you might gather that its strong financials could mean that the stock could
Prius (301257.SZ): 2023 net profit pre-increased by 69.86% to 101.63%
Glonghui, January 22丨Prius (301257.SZ) announced its 2023 annual results forecast. Net profit profit attributable to shareholders of listed companies during the reporting period was 123.0 million yuan to 140.6 million yuan, an increase of 69.86% to 101.63% over the same period of the previous year; net profit profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 10,400.00 million yuan to 124.0 million yuan, an increase of 55.41% to 85.30% over the same period last year. In 2023, the company closely revolves around the established development strategy, takes stability and progress as the general tone, and is active
Prius (301257. SZ) was reduced by shareholder Huiqiao Hongjia by a total of 1,8292 million shares
Prius (301257.SZ) announced that the implementation of the company shareholder Huiqiao Hongjia's equity change plan has been completed, and public holdings have been reduced cumulatively...
SMO ClinPlus CO.,LTD.'s (SZSE:301257) Market Cap Dropped CN¥402m Last Week; Individual Investors Bore the Brunt
Key Insights SMO ClinPlusLTD's significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 6 shareholders own 51% of the
Prius (301257.SZ): Equity distribution for the first three quarters of 2023, 10 allocations of 0.68 yuan, stock registration date: December 8
Glonghui (301257.SZ) announced on December 1, Prius (301257.SZ) announced that the company's equity distribution plan for the first three quarters of 2023 is to distribute RMB 0.68,0000 in cash (tax included) for every 10 shares to all shareholders based on the company's current total share capital of 61,160,000 shares. The share registration date for the current equity distribution is December 8, 2023, and the day before interest is December 11, 2023.
Prius (301257.SZ) shareholders Hongrun Yingke and Zhang Jing reduced their holdings of the company by 5.46%
Prius (301257.SZ) issued an announcement. Recently, the company received separate notices from shareholders Hongrun Yingke and Zhang Jing...
Is SMO ClinPlus CO.,LTD.'s (SZSE:301257) Recent Stock Performance Tethered To Its Strong Fundamentals?
Most readers would already be aware that SMO ClinPlusLTD's (SZSE:301257) stock increased significantly by 29% over the past three months. Given the company's impressive performance, we decided to st
Prius (301257.SZ)'s main shareholder view was that Zhaotai's cumulative holdings reduction ratio reached 3.97% and terminated the holdings reduction plan ahead of schedule
Prius (301257.SZ) announced that Shanghai Guanyou Investment Development Co., Ltd., a shareholder holding 5% or more of the company's shares - Guan...
Do SMO ClinPlusLTD's (SZSE:301257) Earnings Warrant Your Attention?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to investors, even if it currently lacks a track record of revenue and profit. Sometime
Prius (301257.SZ): It is expected that the concentration of the SMO industry will continue to increase and concentrate on leading SMO
GLONGHUI September 7 | Prius (301257.SZ) held a brokerage strategy meeting on September 7, 2023, on “The current competitive pattern of the domestic SMO industry?” The company replied that at present, China's SMO industry is still in the early stages of development, and the market pattern is scattered, showing a competitive pattern where several leading companies coexist with many leading enterprises. With the gradual expansion of customer resources, talent scale, and institutional coverage of leading SMO companies, and accelerated consolidation of technology, brand, and reputation, domestic pharmaceutical supervision policies are favorable to SMO enterprises with innovative project service capabilities. It is expected that the SMO industry will be concentrated
Prius (301257.SZ): By the end of June, the company had undertaken more than 2,700 projects
GLONGHUI September 6 | Prius (301257.SZ) was surveyed by a specific target on September 5, 2023. “May I ask about the company's project status this year?” The company replied that the number of SMO projects implemented by the company also increased steadily in the first half of this year. The projects the company undertook were mainly clinical trials of new drugs that were difficult to manage and complicated, and had accumulated rich experience in project execution. As of June 30, 2023, the company has undertaken more than 2,700 projects, including 44 customer ADC projects, 54 dual resistance projects, and 55 CAR-T projects.
Analysis
Price Target
No Data
